Thymosin Alpha-1 (TA1)

Immune Approved (Asia, Latin America)

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue that plays a key role in immune system regulation. It is the most well-characterized thymic peptide and is produced commercially by solid-phase synthesis. Thymosin Alpha-1 enhances both innate and adaptive immune responses by modulating dendritic cell function, promoting T-cell maturation, and stimulating cytokine production. The peptide is approved in over 35 countries for treatment of chronic hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It has also shown potential in treating other infectious diseases and immunodeficiency conditions.

Key Data

Research Status
Approved (Asia, Latin America)
Half-Life
2 hours
Administration
Subcutaneous injection
Typical Dosage
1.6 mg twice weekly
Molecular Weight
3,108 Da
Molecular Formula
C129H215N33O55

Mechanism of Action

Enhances T-cell function, dendritic cell maturation, and overall immune surveillance.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home